Table 2.
Otolaryngological Symptom Severity According to Groups.
| Otolaryngological Symptom Severity | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Absent (0) | Mild (1) | Moderate (2) | Severe (3) | Very Severe (4) | |||||||||||
| OC + OT | NC + OT | OT | OC + OT | NC + OT | OT | OC + OT | NC + OT | OT | OC + OT | NC + OT | OT | OC + OT | NC + OT | OT | |
| 59 | 22 | 71 | 59 | 22 | 71 | 59 | 22 | 71 | 59 | 22 | 71 | 59 | 22 | 71 | |
| Nasal obstruction | 35 (59.3%) | 9 (41%) | 30 (42.2%) | 8 (13.6%) | 2 (9.1%) | 22 (31%) | 9 (15.2%) | 3 (13.6%) | 10 (14.1%) | 4 (6.8%) | 5 (22.7%) | 8 (11.3%) | 3 (5.1%) | 2 (9.1%) | 1 (1.4%) |
| Rhinorrhea | 27 (45.8%) | 14 (63.6%) | 45 (63.4%) | 14 (23.7%) | 2 (9.1%) | 6 (8.4%) | 10 (16.9%) | 2 (9.1%) | 53 (74.6%) | 5 (8.5%) | 1 (4.5%) | 0 (0%) | 3 (5.1%) | 0 (0%) | 0 (0%) |
| Throat pain | 27 (45.8%) | 15 (68.2%) | 30 (42.2%) | 21 (35.6%) | 4 (18.2%) | 14 (19.7%) | 6 (10.2%) | 1 (4.5%) | 6 (8.4%) | 3 (5.1%) | 2 (9.1%) | 5 (7%) | 2 (3.4%) | 0 (0%) | 1 (1.4%) |
| Postnasal drip | 30 (50.8%) | 7 (31.8%) | 54 (76.1%) | 16 (27.1%) | 7 (31.8%) | 19 (26.8%) | 5 (8.5%) | 6 (27.3%) | 10 (14.1%) | 5 (8.5%) | 2 (9.1%) | 8 (11.3%) | 3 (5.1%) | 0 (0%) | 4 (5.6%) |
| Face pain/heaviness | 42 (71.2%) | 20 (90.9%) | 54 (76.1%) | 7 (11.9%) | 0 (0%) | 10 (14.1%) | 5 (8.5%) | 1 (4.5%) | 5 (7%) | 4 (6.8%) | 1 (4.5%) | 2 (2.8%) | 1 (1.7%) | 0 (0%) | 0 (0%) |
| Dysphonia | 48 (81.3%) | 20 (90.9%) | 29 (40.8%) | 6 (10.2%) | 2 (9.1%) | 10 (14.1%) | 5 (8.5%) | 0 (0%) | 5 (7%) | 0 (0%) | 0 (0%) | 2 (2.8%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Nasal burning | 37 (62.7%) | 19 (86.4%) | 29 (40.8%) | 10 (16.9%) | 1 (4.5%) | 28 (39.4%) | 5 (8.5%) | 2 (9.1%) | 13 (18.3%) | 5 (8.5%) | 0 (0%) | 1 (1.4%) | 2 (3.4%) | 0 (0%) | 0 (0%) |
The symptoms of patients during the clinical course of the disease were evaluated with a 5-point scale ranging from 0 (absent) to 4 (very severe symptoms). Abbreviations: OC = oral corticosteroids; NC = nasal corticosteroids; OT = olfactory training.